See more : PT Duta Intidaya Tbk (DAYA.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Rhythm Pharmaceuticals, Inc. (RYTM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Rhythm Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Admicom Oyj (ADMCM.HE) Income Statement Analysis – Financial Results
- China Construction Bank Corporation (CICHF) Income Statement Analysis – Financial Results
- Ordissimo SA (ALORD.PA) Income Statement Analysis – Financial Results
- MediNavi AG (MDQK.HM) Income Statement Analysis – Financial Results
- COIMA RES S.p.A. SIIQ (CRES.MI) Income Statement Analysis – Financial Results
Rhythm Pharmaceuticals, Inc. (RYTM)
About Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 77.43M | 23.64M | 3.15M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 9.30M | 2.13M | 599.00K | 690.00K | 834.00K | 442.00K | 223.00K | 144.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 68.13M | 21.51M | 2.56M | -690.00K | -834.00K | -442.00K | -223.00K | -144.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 87.99% | 90.98% | 81.01% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 134.95M | 108.63M | 104.13M | 90.45M | 109.45M | 50.34M | 22.89M | 19.59M | 7.15M | 5.28M | 18.02M | 15.68M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 28.08M | 9.52M | 6.31M | 3.43M | 1.21M | 3.43M | 2.46M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 117.53M | 92.03M | 68.49M | 46.13M | 36.55M | 28.08M | 9.52M | 6.31M | 3.43M | 1.21M | 3.43M | 2.46M |
| Other Expenses | 0.00 | -790.00K | 100.00M | 0.00 | 0.00 | 0.00 | -1.86M | 0.00 | -500.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 252.48M | 200.66M | 172.61M | 136.58M | 146.00M | 78.42M | 32.41M | 25.91M | 10.57M | 6.49M | 21.45M | 18.14M |
| Cost & Expenses | 261.79M | 202.80M | 173.21M | 136.58M | 146.00M | 78.42M | 32.41M | 25.91M | 10.57M | 6.49M | 21.45M | 18.14M |
| Interest Income | 13.95M | 4.03M | 447.00K | 2.58M | 5.27M | 4.35M | 566.00K | 33.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 13.89M | 5.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.76M | 1.40M | 1.16M | 690.00K | 834.00K | 442.00K | 223.00K | 144.00K | 500.00K | 6.49M | 20.00K | 17.00K |
| EBITDA | -168.46M | -174.52M | -68.45M | -135.89M | -145.17M | -77.98M | -32.19M | -25.76M | -10.07M | 0.00 | -21.41M | -18.12M |
| EBITDA Ratio | -217.58% | -744.22% | -5,391.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -184.36M | -179.16M | -170.06M | -136.58M | -146.00M | -78.42M | -32.41M | -25.91M | -10.57M | -6.49M | -21.45M | -18.14M |
| Operating Income Ratio | -238.10% | -757.92% | -5,391.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 243.00K | -1.96M | 100.45M | 2.58M | 5.27M | 4.35M | -1.30M | 33.00K | -500.00K | 0.00 | 17.00K | 8.00K |
| Income Before Tax | -184.11M | -181.12M | -69.61M | -134.00M | -140.73M | -74.06M | -33.71M | -25.87M | -11.07M | -6.49M | -21.43M | -18.13M |
| Income Before Tax Ratio | -237.79% | -766.22% | -2,207.10% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 564.00K | 1.96M | -1.61M | -3.27M | -6.11M | 4.35M | 1.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -184.68M | -183.08M | -68.01M | -130.73M | -134.62M | -74.06M | -33.71M | -25.87M | -11.07M | -6.49M | -21.43M | -18.13M |
| Net Income Ratio | -238.52% | -774.52% | -2,156.21% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.20 | -3.51 | -1.37 | -2.96 | -3.70 | -2.39 | -2.54 | -1.55 | -0.66 | -0.64 | -0.43 | -0.36 |
| EPS Diluted | -3.20 | -3.51 | -1.37 | -2.96 | -3.70 | -2.39 | -2.54 | -1.55 | -0.66 | -0.64 | -0.43 | -0.36 |
| Weighted Avg Shares Out | 57.67M | 52.12M | 49.60M | 44.13M | 36.42M | 31.00M | 13.27M | 16.73M | 16.73M | 10.20M | 50.27M | 50.27M |
| Weighted Avg Shares Out (Dil) | 57.67M | 52.12M | 49.60M | 44.13M | 36.42M | 31.00M | 13.27M | 16.73M | 16.73M | 10.20M | 50.27M | 50.27M |
Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old
BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the United Kingdom's Medicines & Healthcare products Regulatory...
Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide
-- Four Pediatric patients treated in French early-access program achieved meaningful weight reduction at three months on setmelanotide therapy -- -- Rhythm announced plans for a new substudy to evaluate setmelanotide therapy in patients with congenital hypothalamic obesity --
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology
BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the publication of results from its Phase 3 VENTURE...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that on November 7, 2024, the Compensation & Management Development Committee of Rhythm's Board...
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer,...
Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2024 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ) Q3 2024 Earnings Conference Call November 5, 2024 5:00 PM ET Company Participants David Connolly - Head of Investor Relations and Corporate Communications David Meeker - Chairman, President and Chief Executive Officer Jennifer Lee -...
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.80. This compares to loss of $0.76 per share a year ago.
Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update
-- Third quarter 2024 net revenue from global sales of IMCIVREE ® (setmelanotide) of $33.3 million -- -- Adult patients with acquired hypothalamic obesity (N=8) achieved mean BMI reduction of 12.8% on setmelanotide therapy at three months in French early-access...
Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024
-- Real-world data showed mean BMI decrease of 12.8% in adult patients with acquired hypothalamic obesity (N=8) at three months on setmelanotide therapy; mean BMI decrease of 21.3% in patients (n=5) who reached six months -- -- Greater reduction in...
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Rhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Source: https://incomestatements.info
Category: Stock Reports